These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 29556919)

  • 1. Recent advances in medical therapy for metastatic urothelial cancer.
    Yuasa T; Urakami S; Yonese J
    Int J Clin Oncol; 2018 Aug; 23(4):599-607. PubMed ID: 29556919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab in the treatment of advanced urothelial cancer.
    Lundgren KT; Farina MS; Bellmunt J
    Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
    Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
    Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status.
    Grivas P; Plimack ER; Balar AV; Castellano D; O'Donnell PH; Bellmunt J; Powles T; Hahn NM; de Wit R; Bajorin DF; Ellison MC; Frenkl TL; Godwin JL; Vuky J
    Eur Urol Oncol; 2020 Jun; 3(3):351-359. PubMed ID: 32423837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
    Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
    Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab for the treatment of bladder cancer.
    Sundahl N; Rottey S; De Maeseneer D; Ost P
    Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frontiers in combining immune checkpoint inhibitors for advanced urothelial cancer management.
    Rebhan K; Laukhtina E; Shariat SF; Gust KM
    Curr Opin Urol; 2020 May; 30(3):457-466. PubMed ID: 32235284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer.
    Yasuoka S; Yuasa T; Nishimura N; Ogawa M; Komai Y; Numao N; Yamamoto S; Kondo Y; Yonese J
    Anticancer Res; 2019 Jul; 39(7):3887-3892. PubMed ID: 31262917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
    Parikh M; Pan CX; Beckett LA; Li Y; Robles DA; Aujla PK; Lara PN
    Clin Genitourin Cancer; 2018 Dec; 16(6):421-428.e1. PubMed ID: 30166228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.
    Brown JR; Koshkin VS
    Eur Urol Focus; 2024 Mar; 10(2):231-233. PubMed ID: 38797658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors for urothelial carcinoma.
    Kim HS; Seo HK
    Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The evolving treatment landscape of metastatic urothelial cancer.
    Roviello G; Santoni M; Sonpavde GP; Catalano M
    Nat Rev Urol; 2024 Oct; 21(10):580-592. PubMed ID: 38702396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update of systemic immunotherapy for advanced urothelial carcinoma.
    Gartrell BA; He T; Sharma J; Sonpavde G
    Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onychomadesis following pembrolizumab treatment for metastatic urothelial carcinoma: A report of two cases.
    Sugihara Y; Kawai T; Yamada D; Furuyama C; Sato Y; Kume H
    Eur J Cancer; 2020 Feb; 126():91-92. PubMed ID: 31923731
    [No Abstract]   [Full Text] [Related]  

  • 19. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
    Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
    Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments and future directions of first-line systemic therapy combined with immunotherapy for advanced or metastatic urothelial carcinoma: a historical perspective on treatment evolution.
    Kawashima A; Ishizuya Y; Yamamoto Y; Kato T; Hatano K; Nonomura N
    Int J Clin Oncol; 2024 Aug; 29(8):1096-1104. PubMed ID: 38850448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.